Segesterone acetate/ethinylestradiol

Ethinylestradiol /
segesterone acetate

Ethinylestradiol (top) and segesterone acetate (bottom)
Combination of
Ethinylestradiol	Estrogen
Segesterone acetate	Progestogen
Clinical data
Trade names	Annovera
Other names	EE/SGA; EE/SA
Routes of administration	Vaginal ring

Ethinylestradiol/segesterone acetate (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains ethinylestradiol, an estrogen, and segesterone acetate, a progestin. It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day, and lasts for a duration of one year. The medication was developed by TherapeuticsMD and was approved for use in the United States on 10 August 2018.

See also

• Combined injectable birth control § Available forms
• List of combined sex-hormonal preparations